Lexeo Therapeutics (LXEO) Income from Non-Controlling Interests (2023)
Lexeo Therapeutics (LXEO) posted Income from Non-Controlling Interests of -$258000.0 for Q4 2023, up 5.15% sequentially from -$272000.0 in Q3 2023.
Powered by 
Analysis
Lexeo Therapeutics (LXEO) Income from Non-Controlling Interests (2023) Analysis & Trends
Lexeo Therapeutics has reported Income from Non-Controlling Interests for 1 years, with the latest figure at -$258000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lexeo Therapeutics | 419.14 Mn | 419.14 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -258,000.00 |
| Sep 30, 2023 | -272,000.00 |